Navigation Links
Manmade antibodies hold biomedical promise
Date:5/19/2010

n the whole process on its head, making the antibody chemically, then finding out what it's an antibody to," Johnston says.

To accomplish this, a 20-unit random sequence of amino acids are joined together like beads on a necklace to form a peptide. By uniting two of these peptide chains, linked together by means of a chemical scaffold, a binding molecule or ligand is created, which can attach to a specific protein with high affinity. The resulting synbody may then be screened against a multitude of human proteins, to find its mate.

The strategy relies on the fact that the binding affinity of two such amino acid sequences is the product of their combined affinity, allowing two peptides with weak attraction to a given protein to be joined to produce a synbody with strong binding properties. Remarkably, the assemblage of both the individual peptides and the synbody are carried out randomly.

The raw material for the synbody comes from a library of 10,000 peptides, with each amino acid sequence randomly composed. As Johnston explains, "the randomness turned out to be the key to all of this, because a random sequence has more flexibility and degrees of freedom than life sequences do." Each resulting linear peptide chain is able to find 2 or 3 points of contact with virtually any protein. When two such peptides are combined to form a synbody, a high-affinity ligand is produced, displaying specificity for a given protein.

Currently, the only limiting technological consideration is the number of proteins that can be placed on an array slide and that capability, as Johnston notes, is rapidly improving. Another key advantage in the use of synbodies is that they remain stable over time, unlike their biological counterparts, making them far more suitable for diagnostic assays.

Exposing random synbodies to multiple proteins helps build a library of effective ligands over time. To create a synbody to a particular disease protein o
'/>"/>

Contact: Joe Caspermeyer
joseph.caspermeyer@asu.edu
480-258-8972
Arizona State University
Source:Eurekalert

Page: 1 2 3

Related medicine news :

1. Biological catch-22 prevents induction of antibodies that block HIV
2. Reportlinker Adds The Future of Monoclonal Antibodies - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis
3. Dana-Farber and Sanford-Burnham Institute license flu-targeting antibodies to Genentech and Roche
4. Low levels of natural antibodies behind stroke
5. Antibodies linked to cardiovascular disease increase in patients with active lupus
6. Biomedical Industry Jobs Critical to California's Economic Recovery, Finds California Healthcare Institute and PricewaterhouseCoopers
7. Entest BioMedical Enters into LOI with Advanced Light Devices to Develop Laser Platform for Stem Cell / Laser COPD Treatment
8. Autism-Supplements.com and Generation Rescue Work Together to Raise Money for Biomedical Autism Treatments
9. Money for Biomedical Research Cut in Recent Years
10. ASH to Encourage High School Students to Pursue Biomedical Research Through Special Symposium and Science Curriculum
11. The Foundation for Biomedical Research Releases New Breast Cancer PSA
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/3/2015)... PINES, FL (PRWEB) June 03, 2015 The ... event as part of the Veterans Health Administration’s (VHA) National ... place in the JC Cobb room located on the first ... 10:00 a.m. to 4:00 p.m. Women Veterans and their ... are invited to attend. To download a printable event flyer, ...
(Date:6/3/2015)... Norcross, GA (PRWEB) June 03, 2015 ... officially named the winner of its 2015 U.S. Education ... Power Portfolio in a college or university in the ... a GIScience student focused on Remote Sensing and Civil ... winning study, titled, “Pavement Surface Cracks Detection and Assessment ...
(Date:6/3/2015)... (PRWEB) June 03, 2015 Johnson & ... pay $7.8 million to resolve a Risperdal lawsuit ( ... tactics the company allegedly used to market the antipsychotic ... Court indicate that the Arkansas Attorney General moved to ... the accord. The Risperdal settlement amounts to just a ...
(Date:6/3/2015)... 2015 On June 22, 2015, Medicare ... drug sensitivity (pharmacogenetic) testing that it has reimbursed since 2009. ... as 19 million of the 49 million Medicare beneficiaries in ... life-threatening adverse drug events.(1) Sadly, if it became a standard ... Medicine, the use of an individual’s genetic information to tailor ...
(Date:6/3/2015)... Array Health , a leading ... that CEO Jonathan Rickert will present at America’s ... 4, 2015. The session will address the how the ... business models in health care, and why they are ... Digital Transformation and the Health Care Enterprise: Driving Business ...
Breaking Medicine News(10 mins):Health News:Bay Pines to Host National Women Veterans Campaign Event June 12 2Health News:Bay Pines to Host National Women Veterans Campaign Event June 12 3Health News:Hexagon Geospatial Announces U.S. Education Challenge Winner at HxGN Live 2015 2Health News:Risperdal Lawsuit News: Johnson & Johnson, Janssen Settle Arkansas Marketing Case for $7.8 Million 2Health News:Risperdal Lawsuit News: Johnson & Johnson, Janssen Settle Arkansas Marketing Case for $7.8 Million 3Health News:Risperdal Lawsuit News: Johnson & Johnson, Janssen Settle Arkansas Marketing Case for $7.8 Million 4Health News:Medicare Limiting Coverage Benefit for Drug Sensitivity Testing on June 22, 2015 2Health News:Medicare Limiting Coverage Benefit for Drug Sensitivity Testing on June 22, 2015 3Health News:Medicare Limiting Coverage Benefit for Drug Sensitivity Testing on June 22, 2015 4Health News:Medicare Limiting Coverage Benefit for Drug Sensitivity Testing on June 22, 2015 5Health News:Medicare Limiting Coverage Benefit for Drug Sensitivity Testing on June 22, 2015 6Health News:Medicare Limiting Coverage Benefit for Drug Sensitivity Testing on June 22, 2015 7Health News:Array Health’s CEO to Present at America’s Health Insurance Plans Institute 2015 2
... the first long-term randomized trial of a chemopreventive agent for ... cancer in the drug-treated group may be attributable to shrinkage ... The study of the Prostate Cancer Prevention Trial, led by ... Gann, is published in the Sept. 12 issue of the ...
... Providers, SEATTLE, Sept. 12 , News Facts -- ... concerns and interests to the 2008 presidential candidates ... online physician community. -- The initiative is enabling U.S. licensed ... via individual web-based videos. Experts from a ...
... Wrinkles, HIGHLANDS, N.J., Sept. 12 Fifty really ... men in their 40s and 50s look better than,their ... can look incredibly sexy at any age. So ... keep the,attention of handsome himbos and beautiful babes? Biocap, ...
... Corporation,(Nasdaq: KNSY ) today announced that it will ... 30, 2007 at 7:00 A.M. Eastern Time on,Friday, October ... be hosting a teleconference,discussing the earnings results on Friday, ... participate in the teleconference call, dial 1-651-291-5254. The,teleconference call ...
... billion dollars. , But an unhealthy kidney costs moreabout ... associate professor in the division of nephrology and hypertension ... about $17 billion a year to care for patients ... currently over 320,000 people undergoing hemodialysis in the United ...
... Centers Head and Neck Cancer Center is teaming up ... cancer. The clinical alliance between Mount Sinai and ENT ... allergy and audiology practice in the tri-state area, together ... quality care, cancer screening and advanced surgical options for ...
Cached Medicine News:Health News:Shrinkage of prostate led to overestimation of cancer risk in trial 2Health News:U.S. Physicians Question Presidential Candidates 2Health News:Cougars Crave Biocap, The Haute Pepper Wrinkle Eraser 2Health News:Kensey Nash Corporation Announces its First Quarter 2008 Earnings Release Date and Teleconference 2Health News:Clinical trials present better alternatives for dialysis patients 2Health News:Mount Sinai & ENT and Allergy Associates, LLP affiliate to fight cancer 2
(Date:6/3/2015)... 2015  SurgiQuest®, Inc. ("SurgiQuest", the "Company"), a ... invasive surgery (MIS) announced today that surgeons have ... procedures.  Adoption has risen rapidly with a 150% ... by the company,s expansion from robotics into the ... to over 45 countries.   The ...
(Date:6/3/2015)... , June 02, 2015 Research and ... of the "Global Neurodegenerative Diseases Market 2015-2019" ... global neurodegenerative diseases market to grow at a ... This report covers the present scenario and ... market for the period 2015-2019. To calculate the ...
(Date:6/3/2015)... 2015  EIP Pharma LLC ( www.eippharma.com ) today ... of VX-745 in Alzheimer,s disease (AD) is underway.  VX-745 ... inhibitor of the alpha isoform of the protein enzyme ... "Recent human genetic data demonstrate that inflammation is ... Alzheimer,s, while the science also indicates the p38 MAPK ...
Breaking Medicine Technology:Rapid Procedure Growth With SurgiQuest's AirSeal System 2Global Neurodegenerative Diseases Market 2015-2019 - Reformulation of Marketed Drugs 2EIP Pharma announces first patient dosing in phase 2 clinical studies of a novel brain-targeted anti-inflammatory drug candidate, VX-745, for the treatment of Alzheimer's disease (AD) 2EIP Pharma announces first patient dosing in phase 2 clinical studies of a novel brain-targeted anti-inflammatory drug candidate, VX-745, for the treatment of Alzheimer's disease (AD) 3
... Inc. ( www.bendresearch.com ), a leading independent drug-formulation development and ... Jim Nightingale, who has worked at the company since 1993, ... Nightingale will succeed Rod Ray, who will ... (CEO) and chairman of the board of directors. ...
... Mass., July 27, 2011 Magellan Biosciences, a ... testing easier, more cost-effective, and less labor intensive, ... Atlanta yesterday at the AACC Clinical Lab Expo. ... laboratories seeking to improve the workflow efficiency, cost-effectiveness, ...
Cached Medicine Technology:Bend Research Inc. Names New President 2Magellan's Dynex® Agility™ ELISA Processor Dramatically Reduces Laboratory Time and Labor in Diagnostic Testing While Ensuring the Most-Accurate Results 2Magellan's Dynex® Agility™ ELISA Processor Dramatically Reduces Laboratory Time and Labor in Diagnostic Testing While Ensuring the Most-Accurate Results 3
With the Symphony family of Pacemakers, Ela presents the most advanced technology on the market. Symphony, lighter than a passport, will take your patients further, offering fast follow-up, using new...
Gentle curve facilitates less traumatic removal from eye. Increased length ideal for myopic eyes...
Sleeve extends 3mm beyond end, .90mm (20G) probe, 1.4mm (17G) sleeve...
Ideal for short scleral tunnel and trabecular meshwork incisions...
Medicine Products: